Study on TCM Syndrome Classification of Idiopathic Pulmonary Fibrosis Based on Metabolomics
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 75
- Locations
- 1
- Primary Endpoint
- biomarkers detected in metabolites
Study Overview
Brief Summary
The pathogenesis of idiopathic pulmonary interstitial fibrosis is complex, and there is no specific biomarkers, the treatment effect is not such useful. Currently, it is discovered that Chinese medicine treatment may be effective. The investigators select patients with idiopathic pulmonary interstitial fibrosis and healthy controls, use metabolomics to study the biological characteristics of idiopathic pulmonary interstitial fibrosis, screen biomarkers of IPF, and label different TCM syndromes of IPF, explore the biological nature of IPF TCM syndromes, find the biological changes that occur during the development and progression of IPF and explore the metabolite marker clusters of IPF. Furthermore, the results of this study may find its diagnostic significance for IPF and Looking for potential targets for future treatment of IPF.
Study Design
- Study Type
- Observational
- Observational Model
- Case Control
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 50 Years to 85 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Case group inclusion criteria
- •According to the diagnostic criteria published in 2015, the New Guidelines for the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis, jointly developed by the American Thoracic Society, the European Respiratory Society, the Japanese Respiratory Society, and the Latin American Thoracic Society;
- •aged 50 to 85 years old;
- •Control group inclusion criteria:
- •Health people match on the age (±3 years old) and gender with case group with 1:1 rate at the same time.
Exclusion Criteria
- •Case group exclusion criteria:
- •Those with severe heart, liver, kidney and other organ dysfunction or suffering from blood diseases;
- •with malignant tumors;
- •Severely infected people;
- •Pregnant and lactating women;
- •mental illness, serious obstacles and those who are unwilling to cooperate;
- •Control group exclusion criteria:
- •Those with severe heart, liver, kidney and other organ dysfunction or blood disease;
- •With malignant tumors;
- •Chest X-ray or chest low-dose CT suggesting intra-pulmonary interstitial fibrosis;
- •With chronic pulmonary diseases such as pulmonary interstitial disease, chronic obstructive pulmonary disease, and bronchial asthma;
- •With connective tissue disease and those with a history of exposure to occupational diseases;
- •Mental illness, serious obstacles and unwilling to cooperate.
Outcomes
Primary Outcomes
biomarkers detected in metabolites
Time Frame: 1 year
Metabolomics of serum based on mass spectrometry.It is non-targeted metabolomics.The study is to find the target metabolite to distinguish IPF.
Secondary Outcomes
- Pulmonary function Pulmonary function(1 year)
- High-resolution chest CT total score (CT-Tot)(1 year)
- Six Minute Walk Test(6MWT)(1 year)
- St. George's Respiratory Questionnaire(1 year)